Quantum BioPharma Ltd. Makes Strategic Investment in GameStop Corp.

Toronto, July 22, 2025 — Quantum BioPharma Ltd., a biopharmaceutical company focused on developing innovative therapies for neurodegenerative disorders, announced today that it has purchased 2,000 shares of GameStop Corp. (NYSE: GME). This acquisition is intended to be held on the company’s balance sheet as a strategic investment.

The decision to invest in GameStop has led to a noticeable decline in Quantum BioPharma’s stock price. Reports from multiple financial news sources, including StockWatch, Investing.com, and Seeking Alpha, highlighted the stock’s fall following the announcement of the GameStop share purchase.

Quantum BioPharma, listed on the Canadian National Stock Exchange, has a market capitalization of 91,310,000 CAD. As of July 21, 2025, the company’s close price was 29.8 CAD, with a 52-week high of 52 CAD on June 19, 2025, and a 52-week low of 3.9 CAD on December 19, 2024. The company’s price-to-earnings ratio stands at -1.46.

In addition to the GameStop investment, Quantum BioPharma has been active in other financial maneuvers. On June 27, 2025, the company completed a non-brokered private placement of class A multiple voting shares at a price of $50 per share. This move is part of Quantum BioPharma’s strategy to build a robust portfolio of innovative assets and biotech solutions.

Furthermore, Quantum BioPharma’s licensee, Unbzzd Wellness Inc., launched a $5 million Regulation D capital raise on June 26, 2025. This initiative aims to fund growth and potentially pave the way for an initial public offering. The capital raise is being supported by MZ Digital, a leading marketing firm, and the crowdfunding platform Dealmaker.

Quantum BioPharma continues to focus on its core mission of developing therapies for neurodegenerative disorders while exploring strategic financial opportunities to enhance its market position.